Since induced pluripotent stem cells (iPSCs) were first produced in 2006 from mouse cells and in 2007 from human cells, research scientists have recognized the wide-ranging potential of the cell type, including the possibility of using them in drug and toxicology screening, disease modeling, and cellular therapy applications ranging from gene correction, to whole tissue regeneration, individualized medicine, and more.
Since the discovery of iPSCs, the commercial sector has also recognized the huge profits that could potentially be generated from the cell type, and the question being explored among the private sector has been how to generate maximal commercial value through the development of iPSC applications and technologies.